The randomised Complete versus Lesion-only PRimary percutaneous coronary Intervention Trial: Cardiovascular Magnetic Resonance imaging substudy (CvLPRIT-CMR)

Gerry P McCann,^{1,2*} Jamal N Khan,^{1,2} John P Greenwood,³ Sheraz A Nazir,¹ Miles Dalby,⁴ Nick Curzen,⁵ Simon Hetherington,⁶ Damian J Kelly,⁷ Daniel J Blackman,³ Arne Ring,^{8,9} Charles Peebles,⁵ Joyce Wong,⁴ Thiagarajah Sasikaran,^{10,11} Marcus Flather,^{12,13} Howard Swanton¹⁴ and Anthony H Gershlick^{1,2}

- ¹Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK
- ²NIHR Leicester Cardiovascular Biomedical Research Unit, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK
- ³Multidisciplinary Cardiovascular Research Centre and The Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
- ⁴Department of Cardiology, Royal Brompton and Harefield Foundation Trust, Harefield Hospital, Middlesex, UK
- ⁵Department of Cardiology, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK
- ⁶Department of Cardiology, Kettering General Hospital, Kettering, UK
- ⁷Department of Cardiology, Royal Derby Hospital, Derby, UK
- ⁸Leicester Clinical Trials Unit, University of Leicester, Leicester, UK
- ⁹Department of Mathematical Statistics and Actuarial Science,
- University of the Free State, Bloemfontein, South Africa
- ¹⁰Clinical Trials and Evaluation Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK
- ¹¹Imperial Clinical Trials Unit, Imperial College London, London, UK
- ¹²Clinical Trials Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK
- ¹³Norwich Medical School, University of East Anglia, Norwich, UK
- ¹⁴Department of Cardiology, The Heart Hospital, University College London Hospitals, London, UK

*Corresponding author

Declared competing interests of authors: Dr McCann reports grants from Institut de Recherches Internationales Servier and Menarini International, outside the submitted work. Dr Curzen reports grants and personal fees from St Jude Medical and Haemonetics, grants from Medtronic, personal fees from Abbott Vascular and Heartflow, and non-financial support from Volcano Corporation, outside the submitted work. Dr Dalby reports providing consultancy services for Medtronic, Boston, AstraZeneca, Daichii Sankyo–Eli Lilly alliance and Sanofi and receiving grants from Abbott Vascular and Daichii Sankyo–Eli Lilly alliance, outside the submitted work. Professor Ring has received conference travel expenses from Boehringer Ingelheim, personal consultancy fees from Roche and research funding from Novartis outside the submitted work. Professor Flather reports serving on advisory and speaker panels for AstraZeneca and Menarini International outside the current work.

Published January 2016 DOI: 10.3310/eme03010

Plain English summary

CvLPRIT-CMR study

Efficacy and Mechanism Evaluation 2016; Vol. 3: No. 1 DOI: 10.3310/eme03010

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Plain English summary

C pecialist heart doctors increasingly treat patients who suffer large heart attacks as a matter of urgency with a procedure performed under local anaesthetic. The blocked blood vessel (artery) that causes the heart attack is opened by inserting a small metal scaffold (stent) at the blockage to hold the artery open. Up to 50% of patients treated in this way also have other narrowed, but not totally blocked, heart arteries. Two recent studies in patients with heart attacks and multiple narrowed arteries have suggested that treating all of the narrowed arteries may be better than just treating the blocked artery. However, there is concern that the longer procedure, and putting in more stents, may cause more damage to the heart. We studied 203 patients having a heart attack who were randomly assigned to have only the blocked artery (105 patients) or all the narrowings treated (98 patients) in seven hospitals in England. We assessed the amount of heart muscle damage that occurred using magnetic resonance imaging. Patients were more likely to have more than one area of heart muscle damage if all of their heart arteries were treated than if only the blocked artery was treated (22% vs. 11% of patients). However, the percentage of the heart that was damaged was not increased (12.6% vs. 13.5%) and the heart function 3 days and 9 months after treatment was similar with both treatments. The results of this study provide reassurance that specialists treating patients with a heart attack can open more than one narrowed artery without increasing the total amount of heart damage.

© Queen's Printer and Controller of HMSO 2016. This work was produced by McCann *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)

ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Efficacy and Mechanism Evaluation journal

Reports are published in *Efficacy and Mechanism Evaluation* (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting 'science driven' studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: http://www.nets.nihr.ac.uk/programmes/eme

This report

The research reported in this issue of the journal was funded by the EME programme as project number 10/27/01. The contractual start date was in April 2011. The final report began editorial review in January 2015 and was accepted for publication in July 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2016. This work was produced by McCann *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

Efficacy and Mechanism Evaluation Editor-in-Chief

Professor Raj Thakker May Professor of Medicine, Nuffield Department of Medicine, University of Oxford, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson Director of NETSCC, HTA, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie Health Services Research Unit, University of Aberdeen, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk